Zercepac

Zercepac (trastuzumab) is a targeted therapy used in cancer treatment. This monoclonal antibody works by interfering with HER2 protein activity. Suitable for metastatic and early-stage breast cancer. Consult a healthcare provider for suitability.

Trastuzumab is prescribed for HER2-positive breast cancer and metastatic gastric cancer. It may be used alone or combined with chemotherapy. Patients often ask what is trastuzumab used for, particularly in early-stage or advanced settings. HER2 testing is typically required before use.

Trastuzumab may cause side effects like fever, chills, or nausea during infusion. Some patients report fatigue or headache afterward. These effects vary by individual and treatment stage. Monitoring is recommended throughout therapy.

Keep this medication refrigerated and protect from light. Do not freeze or shake the vial. Only trained professionals should prepare and administer trastuzumab. Patients should report any signs of infection or breathing difficulties immediately.

Trastuzumab may interact with other chemotherapy drugs or medications affecting heart function. Avoid live vaccines during treatment. Certain blood pressure medications may require monitoring. Always inform your doctor about all current medications.